Confirm effectiveness of vaccine against lung cancer
HAVANA, May 27 Specialists from the Center for Molecular Immunology closed in Camagüey the Phase IV clinical trial, developed nationwide, to consolidate the effectiveness of the Cuban therapeutic vaccine against non-small cell lung cancer CIMAvax-EGF.
During the Clinical Trials Management Workshop, held this Wednesday in the capital of Camagüey, Dr. Mayra Ramos, head of the Department at said institution, explained that the drug has been approved by the regulatory agency since 2008 and has reached some 25,000 people.
The directive highlighted the work of the people from Camagüey and affirmed that the study that concludes ratifies the drug as optimal for treating lung cancer.
The Molecular Immunology Center also conducts 30 clinical trials, and Camagüey participates in eight, with the request to join another seven.
